Depression|Inhibitors Agonists Modulators Antagonists|HmoBio.com

Request The Product List ofDepression Depression

Major depressive disorder, often referred to as major depression, is a heterogenous condition with complex and diverse neurobiological etiologies. Depression is characterized by a triad of symptoms: low or depressed mood, anhedonia and low energy or fatigue. Approximately 15% of the population in developed countries has been affected by depression in their lifetime and the chance of developing depression is twice as high in women. 40-50% of depressive causes are inheritable (genes as yet unidentified) and the remaining 50-60% of causes are caused by environmental stressors.

Pathogenesis of Depression

Traditionally, depression has been described as a disease of decreased monoamine function within the brain (also known as the monoamine hypothesis). Brain areas specifically involved are thought to include the hippocampus, prefrontal and cingulate cortex, and the amygdala. In addition the dopaminergic reward pathway, in particular the nucleus accumbens, and the hypothalamus may also be involved, and have been identified due to the symptoms of anhedonia, and abnormalities in sleep, appetite and circadian rhythms respectively, which are prevalent in depressed patients.

Depression may also be caused by an enhancement of biological stress-response mechanisms, especially the hypothalamic-pituitary-adrenal (HPA) axis, is a common feature of depression, which is manifested by increased corticotrophin releasing factor (CRF) expression in the hypothalamus and cerebrospinal fluid (CSF).

Pharmacological Intervention

The main obstacle for depression research has been the lack of animal models for some depressive symptoms, such as guilt and suicidal ideology. This has hampered efforts to fully understand the disease and it remains an area of intense research.

Current pharmacological interventions for depression focus on potentiation of the monoamine system. Tricyclic antidepressants act by inhibiting serotonin and/or noradrenalin uptake and monoamine oxidase (MAO) inhibitors reduce the enzymatic breakdown of serotonin, noradrenalin and dopamine. Novel pharmacological targets focusing on non-monoamine systems, such as CRF antagonists, GR antagonists, cytokines, melatonin receptoragonists, TrkB agonists, histone deacetylase (HDAC) inhibitors and κ-opioid receptor antagonists, are currently being developed.

Cat. No.	Product Name	CAS No.	Information
H9364	NV-5138 hydrochloride	2639392-70-2	NV-5138 hydrochloride is a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 hydrochloride is used for antidepressant studies.
H9363	NV-5138	2095886-80-7	NV-5138 is a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 is used for antidepressant studies.
H9349	Ropanicant hydrochloride	2414674-71-6	Ropanicant hydrochloride(SUVN-911) is a potent, selective, brain penetrated and orally bioavailable neuronal nicotinic acetylcholine α4β2 receptor antagonist, with a Ki of 1.5 nM. SUVN-911 has antidepressant activity.
H9348	Ropanicant	2414674-70-5	Ropanicant(SUVN-911) is a potent, selective, brain penetrated and orally bioavailable neuronal nicotinic acetylcholine α4β2 receptor antagonist, with a Ki of 1.5 nM. SUVN-911 has antidepressant activity.
H3229	SSR125543	752253-39-7	SSR125543 (Crinecerfont, SSR-125543) is a potent, nonpeptide, orally active corticotropin-releasing factor (CRF) receptor CRF1 antagonist, shows anxiolytic- and antidepressant-like activities in vivo.
H4598	JNJ-54175446	1627902-21-9	JNJ-54175446 is a potent and selective, brain penetrant P2X7 ion channel antagonist with pIC50 of 8.46 and 8.81 for hP2X7 and rP2X7, respectively; exhibits an excellent pharmacokinetic profile, good partitioning into the CNS and shows robust in vivo target engagement; orally active.
H4569	JNJ-39393406	953428-73-4	JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM; does not act on α4β2, α3β4 or 5-HT3A channels, as well as α4β2, α3β4 or 5 HT3A channels, and it does not interacts with a panel of 62 receptors and enzymes; shows bell-shaped dose-response activity in the auditory evoked potential (AEP) in DBA2 mice (0.63–5 mg/kg s.c., lower and higher doses were inactive), and model for sensory gating and the attentional set-shifting in rats.
H4550	Radafaxine hydrochloride	106083-71-0	A potent metabolite of bupropion; selectivly inhibits the reuptake of norepinephrine over dopamine; DAT and NET transporters inhibitor, and nAChR family modulator.
H4548	Paroxetine hydrochloride hemihydrate	110429-35-1	An antidepressant of the selective serotonin reuptake inhibitor (SSRI) class; also shows to be a selective inhibitor of GRK2 activity both in vitro and in living cells; induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.
H4547	Paroxetine hydrochloride	78246-49-8	An antidepressant of the selective serotonin reuptake inhibitor (SSRI) class; also shows to be a selective inhibitor of GRK2 activity both in vitro and in living cells; induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.

Select Your Country or Region

Request The Product List ofDepression Depression

Request The Product List

* Indicates a Required FieldYour information is safe with us.